Autoantibodies against GFAP may represent a new and early serum marker of high diabetes ... (1:150), 3.5, 5, 6, 8, 10 and 20 weeks old, respectively; lane 8, 1:1,000 IgG GFAP antibody. B-and T ...

Shawn Winer, Hubert Tsui, Ambrose Lau, Aihua Song, Xiaomao Li, Roy K. Cheung, Anastazia Sampson, Fatemeh Afifiyan, Alisha Elford, George Jackowski, Dorothy J. Becker ...

Type 1 diabetes is an immune-mediated disease ... T cells in a sea of nonspecific bystanders can drive complete beta-cell destruction 15, the question of whether there is a particular TCR that ...

MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...

Researchers have found that end-stage renal disease (ESRD) is much more prevalent in patients with slowly progressive type 1 ...

Type 1 diabetes (T1D) is an autoimmune condition characterised by the destruction of insulin-producing beta cells in the pancreas. Unlike type 2 diabetes, which is often linked to lifestyle ...

CellTrans has claimed the first FDA approval for a cell therapy used to treat type 1 diabetes, consisting of insulin-producing islet beta cells taken from deceased donors. The Chicago-based ...

(Beta cell destruction leads to type 1 diabetes). The squiggly "tail" on the T cells, which switches from blue to red to yellow, is a tracking mechanism inserted by the researchers to record the T ...

T-cell plasticity Plasticity of Th17 cells as a marker of aggressive beta-cell destruction Although beta-cell autoantibodies are useful for the identification of the children at risk of type 1 ...